

FEB 22 2005

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	10/727,335
Filing Date	December 3, 2003
First Named Inventor	Hammond, David J.
Art Unit	1645
Examiner Name	
Attorney Docket Number	51821-0101 (51821/295084)

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

/Agnieszka Boesen/

Date Considered

11/03/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes for USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9189 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/727,335
		Filing Date	December 3, 2003
		First Named Inventor	Hammond, David J.
		Art Unit	1645
		Examiner Name	
(Use as many sheets as necessary)		Attorney Docket Number	51821-0101 (51821/295084)
Sheet	2	of	2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AB	2	"International Search Report." Conducted for International Application No. PCT/US03/38343. Patent Cooperation Treaty: November 17, 2004.	
AB	3	Schatzl, et al. "Prion Protein Gene Variation Among Primates." J. Mol. Biol. 1995, Vol. 245, pp 362-374.	

Examiner Signature	/Agnieszka Boesen/	Date Considered	11/03/2006
-----------------------	--------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Application Number	10/727,335
Filing Date	12/03/2003
First Named Inventor	David J. Hammond
Group Art Unit	1645
Examiner Name	Not Assigned Yet
Attorney Docket Number	21267-201

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
AB	15		WO 01/77687		V.I. Technologies, Inc.	10-18-2001		
AB	16		WO 03/016904		Campell	02-27-2003		
AB	17		WO 92/00091		Biologand, Inc.	01-09-1992		
Examiner Signature		/Agnieszka Boesen/				Date Considered	11/03/2006	

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. 1503-1506 (2000) :1503-1506 (2000))PTO/SB/08A (08-00)

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/727,335
		Filing Date	12/03/2003
		First Named Inventor	David J. Hammond
		Group Art Unit	1645
		Examiner Name	Not Assigned Yet
Sheet 2	of 3	Attorney Docket Number	21267-201

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
AB	18	AUBRY <i>et al.</i> , "N-Methyl Peptides. IV. Water and Beta-Turn in Peptides. Crystal Structure of N-Pivaloyl-L-Prolyl-N, N'-Dimethyl-D-Alaninamide in the Anhydrous and Monohydrated States", <i>Int. J. Pept. Protein Res.</i> , 18: 195-202 (1981).	
AB	19	CAUGHEY, B., <i>et al.</i> , "Binding of the Protease-Sensitive Form of Prion Protein PrP to Sulfated Glycosaminoglycan and Congo Red", <i>Journal of Virology</i> , 68: 2135-2141 (1994).	
AB	20	DEGRADO, W.F., "Design of Peptides and Proteins", <i>Adv. Protein Chem.</i> :39, 51-124, (1988).	
AB	21	DEVLIN, J.J. <i>et al.</i> , "Random Peptide Libraries: A Source of Specific Protein Binding Molecules", <i>Science</i> : 249, 404-406 (1990).	
AB	22	FISCHER, M.B. <i>et al.</i> , "Binding of Disease-Associated Prion Protein to Plasminogen", <i>Nature</i> : 408, 479-483 (2000).	
AB	23	FURKA, A. <i>et al.</i> "General Method for Rapid Synthesis of Multicomponent Peptide Mixtures", <i>Int. J. Peptide Protein Res.</i> :37, 487-493 (1991).	
AB	24	INGROSSO, L., <i>et al.</i> , "Congo Red Prolongs the Incubation Period in Scrapie-Infected Hamsters", <i>Journal of Virology</i> : 69, 506-508 (1995).	
AB	25	JAMESON, B.A. <i>et al.</i> , "A Rationally Designed CD4 Analogue Inhibits Experimental Allergic Encephalomyelitis", <i>Nature</i> : 368, 744-746 (1994).	
AB	26	KASCSAK, R.J., <i>et al.</i> , "Immunodiagnosis of Prion Disease", <i>Immunological Invest.</i> : 26, 259-268 (1997).	
AB	27	LAM, K.S. <i>et al.</i> , "A New Type of Synthetic Peptide Library for Identifying Ligand-Binding Activity", <i>Nature</i> : 354,82-84 (1991).	
AB	28	Soto <i>et al.</i> , "Reversion Of Prion Protein Conformational Changes By Synthetic β -Sheet Breaker Peptides", <i>LANCET</i> : 355, 192-197 (2000).	
AB	29	MERRIFIELD, B. "Solid Phase Synthesis", <i>Science</i> : 232, 341-3479 (1986).	
AB	30	NEEDLEMAN, S.B. <i>et al.</i> "A General method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins", <i>J. Mol. Biol.</i> : 48, 443-453 (1970).	
AB	31	PEARSON, W.R. <i>et al.</i> "Improved Tools for Biological Sequence Comparison", <i>Proc. Natl. Acad. Sci. U.S.A.</i> :85, 2444-2448 (1988).	
AB	32	PRIOLA, S.A., <i>et al.</i> , "Porphyrin and Phthalocyanine Antiscrapie Compounds", <i>Science</i> : 287, 1503-1506 (2000).	
AB	33	PRUSINER, S.B., "Molecular Biology of Prion Diseases", <i>Science</i> : 252, 1515-1522 (1991).	

Substitute for Form 1449/APTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(use as many sheets as necessary)</p>		Complete if Known	
		Application Number	10/727, 335
		Filing Date	12/03/2003
		First Named Inventor	David J. Hammond
		Group Art Unit	1645
		Examiner Name	Not Assigned Yet
		Attorney Docket Number	21267-201
Sheet	3	of	3

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
AB	34	ROSE <i>et al.</i> "Turns In Peptides And Proteins", <i>Molecular Biology of Prion Diseases</i> Adv. Protein Chem.: 37, 1-109 (1985).	
AB	35	SAFAR, J. <i>et al.</i> , "Eight Prion Strains Have PrP(Sc) Molecules With Different Conformations", <i>Nature Medicine</i> : 4, 1157-1165 (1998).	
AB	36	SAMSON, W.K. <i>et al.</i> "A 35 Amino Acid Fragment of Leptin Inhibits Feeding in the Rat", <i>Endocrinology</i> : 137, 5182-5185 (1996).	
AB	37	SOTO, C. <i>et al.</i> , "Reversion of Prion Protein Conformational Changes in Synthetic Beta-Sheet Breaker Peptides", <i>Lancet</i> : 355, 192-197 (2000).	
AB	38	STOCKELL, <i>et al.</i> , "Prion Protein Selectively Binds Copper(II) Ions", <i>Biochemistry</i> : 37, 7185-7193 (1998).	
AB	39	TAGLIAVANI, F., <i>et al.</i> , "Effectiveness of Anthracycline Against Experimental Prion Diseases in Syrian Hamsters," <i>Science</i> : 276, 1119-1122 (1997).	
AB	40	CASPI <i>et al.</i> , "The Anti-Prion Activity Of Congo Red", <i>J. Biol. Chem.</i> : 273, 3484-3489 (1999).	
AB	41	McHattle <i>et al.</i> , "Clusterin Prevents Aggregation Of Neuropeptide 106-126 <i>In Vitro</i> ", <i>Biochem. Biophys. Res. Commun.</i> : 259, 336-340 (1999).	

Examiner Signature	/Agnieszka Boesen/	Date Considered	11/03/2006
-----------------------	--------------------	--------------------	------------

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.